dm+d

40556005

Articles

Suggestions for Therapeutic Drug Monitoring in Adults in Primary Care

29 September 2020This document is intended to support local discussions on how to monitor commonly prescribed high risk medicines in primary care.    The monitoring parameters cited…

The Use of Generic Anti Epileptics Drugs in Patients with Epilepsy

28 September 2020Consensus views of the Pharmaceutical Market Support Group and the UK Clinical Pharmacists Association: Neurosciences Group on the safety and appropriateness of switching between brand…

Safety in Lactation: Control of epilepsy

21 September 2020Choice will depend on clinical condition, and should primarily be based on suitability for the patient, rather than safety during breastfeeding. Whilst sodium valproate  is…

Switching between liquid and tablet/capsule formulations – Which medicines require extra care?

17 July 2020For a small number of medicines, there are differences in equivalent doses of oral formulations of the same medicine. This needs to be considered when…

What is a suitable combined oral contraceptive pill in a patient who is taking hepatic enzyme-inducing drugs, such as carbamazepine, phenytoin, rifampicin or rifabutin?

16 May 2019This updated Medicines Q&A provides advice on a suitable oral contraceptive that can be used in a woman using an enzyme-inducing anti-epileptic or anti-tubercle drug.…
Search Articles

Medicine Compliance Aid Stability

genericNon-proprietary

Non-proprietary
generic
Tablets 100mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Use for up to 7 days in a MCA.
23 February 2015

EpanutinPfizer Ltd

Pfizer Ltd
Epanutin
Capsules 25mg, 50mg, 100mg, 300mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Use for up to 7 days in a MCA.
23 February 2015

Epanutin InfatabsPfizer Ltd

Pfizer Ltd
Epanutin Infatabs
Tablets chewable 50mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Use for up to 7 days in a MCA.
23 February 2015

Lactation Safety Information

Oral for epilepsy

Oral
for epilepsy
Suitable alternative antiepileptic
Moderate level of published evidence of use in breastfeeding
Small amounts in breast milk
Used in full-term neonates from birth
Single case report of methemoglobinemia in breastfed infant
Case reports of sedation and poor feeding in breastfed infants; other concomitant drugs may have been involved
29 July 2020